HomeFile

File

View Category
Acute coronary syndromes

5-year TVF and MACCE in patients with deferred of revascularization after FFR: Is FFR enough?

Fractional flow reserve (FFR) has been shown effective and safe by different studies, yet not at 5...
solaci -
Learn More
Peripheral vascular disease

ACC 2022 | SPYRAL HTN-ON: Is It Time to Start Using Renal Denervation?

Thirty-eight patients were enrolled in the renal denervation (RDN) group, and 42 in the control group.  The mean...
solaci -
Learn More
Acute coronary syndromes

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two...
solaci -
Learn More
Other

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device....
solaci -
Learn More
Antiplatelet

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent...
solaci -
Learn More
Antiplatelet

ACC 2022 | BENTRACIMAB

This study was presented in phase 2, in a healthy population between 50 and 80 years of...
solaci -
Learn More
Acute coronary syndromes

ACC 2022 | COMPLETE

Percutaneous coronary intervention improves angina related quality of life in AMI patients with multivessel disease. The COMPLETE...
solaci -
Learn More
Acute coronary syndromes

ACC 2022 | PACMAN AMI

Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous...
solaci -
Learn More